Clinical performance of the Lumipulse G NfL CSF assay in cases with AD and FTD

Background Neurofilament light chain (NfL) is a fluid biomarker of axonal damage reported to be elevated in cases with dementia, and particularly in FTD. In this study we evaluate the performance of a recently developed NfL assay to be analyzed through the Lumipulse chemiluminescent platform, which is frequently available in clinical settings for the study of AD core biomarkers. Method We evaluated CSF NfL levels using the Lumipulse G600II platform (Fujirebio, Iberia) in 70 cases, including 33 patients with AD (supported by CSF biomarkers consistent with an A+T+(N)+ classification scheme), 26 with confirmed FTD (typical phenotype and CSF with a A‐T‐ profile), and 11 controls. NfL was also determined in plasma samples of the same cases by single molecule array (SIMOA) with a Quanterix assay. We analyzed the correlation of NfL as measured in these two samples by the two different platforms and their value to discriminate between AD and FTD cases. Result NfL in CSF was higher in FTD (mean‐SD= 2417‐2326 pg/mL) than in AD cases (1144‐594, p=0.07) and controls (809‐327, p=0.03), with no differences between AD and controls. The same applied for plasma NfL with more remarkable statistical differences: FTD (mean‐SD= 37‐21) vs AD cases (19‐7, p>0.001) and vs controls (18‐7, p=0.007). There was a significant linear correlation between NfL values in CSF and plasma in all cases (Pearson R=0.84, p